ArticleJBMR plus2025
Effects of romosozumab and teriparatide on hip bone using 3D-SHAPER in postmenopausal women with osteoporosis.
Article in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Concerns regarding the critical evaluation of 3D-Shaper.JBMR plus · 2026Article
- Romosozumab super-responders in clinical practice: insights from a large Italian multicenter cohort of women with severe postmenopausal osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Assessing cortical bone changes with Romosozumab after one year: Insights from an exploratory HR-pQCT study.Bone reports · 2026Article
- Analyzing the effect of osteoporosis drug treatments on femoral strength using 3D-DXA finite elements modelling.Journal of clinical densitometry : the official journal of the International Society for Clinical DensitometryObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DXA-based 3D-modeling (3D-DXA) of the hip was used to assess estimated changes in bone integral, cortical, and trabecular parameters and analyze 3D anatomical distribution of changes in bone parameters over time in women who transitioned to romosozumab or teriparatide following treatment with oral bisphosphonates in STRUCTURE and in treatment-naïve women in a romosozumab phase 2 dose-ranging study (Phase 2 study). Data from women who had hip DXA scans at baseline and months 6 and 12 in STRUCTURE or baseline and months 3, 6, and 12 in the Phase 2 study and provided consent for future research were analyzed. 3D-SHAPER software was applied to generate patient-specific 3D-models from hip DXA scans. Percentage changes from baseline in areal BMD (aBMD), integral volumetric BMD (vBMD), cortical thickness, cortical vBMD, cortical surface BMD (sBMD), and trabecular vBMD were evaluated. Data of 308 women from STRUCTURE (romosozumab, 160; teriparatide, 148) with 3D-DXA assessments at baseline and months 6 and 12 were analyzed. Greater increases in aBMD, integral vBMD, cortical thickness, cortical vBMD, cortical sBMD, and trabecular vBMD were seen by month 6 following treatment with romosozumab vs teriparatide (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.